Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 4(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01599897Phase 1Completed

Phase 1 ID93 + GLA-SE Vaccine Trial in Healthy Adult Volunteers

Role: collaborator

NCT00194636Phase 4Suspended

Effectiveness of Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia)

Role: collaborator

NCT00194610Phase 4Completed

Botox as a Treatment for Interstitial Cystitis in Women

Role: collaborator

NCT00194623Phase 4Terminated

Botox as a Treatment for Chronic Male Pelvic Pain Syndrome

Role: collaborator

All 4 trials loaded